Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:activeIngredient |
gptkb:rituximab
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:affiliatedWith |
antineoplastic agent
immunosuppressant chimeric monoclonal antibody |
| gptkbp:approvedBy |
gptkb:Swissmedic
gptkb:European_Medicines_Agency 1997 |
| gptkbp:ATCCode |
L01XC02
|
| gptkbp:brand |
gptkb:rituximab
|
| gptkbp:contraindication |
hypersensitivity to rituximab
severe active infections |
| gptkbp:developedBy |
gptkb:Roche
|
| https://www.w3.org/2000/01/rdf-schema#label |
MabThera
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Genentech
gptkb:Roche |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
infections chills neutropenia infusion reactions |
| gptkbp:target |
gptkb:CD20
|
| gptkbp:usedFor |
gptkb:granulomatosis_with_polyangiitis
leukemia chronic lymphocytic leukemia rheumatoid arthritis microscopic polyangiitis |
| gptkbp:bfsParent |
gptkb:rituximab
gptkb:Roche gptkb:Rituxan |
| gptkbp:bfsLayer |
6
|